Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine
- PMID: 32129958
- DOI: 10.36849/JDD.2020.4835
Multidisciplinary Real-World Experience With Bilastine, a Second Generation Antihistamine
Abstract
Introduction: Allergic conditions frequently require treatment with antihistamines. First-generation antihistamines can potentially interfere with restful sleep, cause “morning after” effects, impair learning and memory, and reduce work efficiency. Second-generation antihistamines, such as bilastine, have been demonstrated to decrease allergy symptoms effectively without causing night-time sleep disturbances and related adverse events. Method: A real-world case project was developed to help optimize patient care by recognizing the role bilastine can play for allergic conditions where antihistamine treatment is needed. The presented real-world patient cases conducted by the panel members are supported with evidence from the literature, where available. Any discussion concerning off-label use should be considered an expert opinion only. Results: The real-world cases presented here used bilastine in conditions such as perennial and seasonal allergic rhinitis, chronic urticaria, as well as urticarial vasculitis and pruritus associated with inflammatory skin conditions. The treated patients were between 9 and 76-years old providing information on a full spectrum of patients that require treatment with antihistamines. Conclusions: The presented real-world cases using the second-generation antihistamine, bilastine, demonstrated favorable outcomes for the treated patients. While effectively relieving symptoms, the antihistamine was reported to be safe and well-tolerated. J Drugs Dermatol. 2020;19(2)145-154. doi:10.36849/JDD.2020.4835
Similar articles
-
Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients.Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):820-828. doi: 10.26355/eurrev_201802_14318. Eur Rev Med Pharmacol Sci. 2018. PMID: 29461615 Clinical Trial.
-
How bilastine is used to treat allergic rhinitis and urticaria in children.Immunotherapy. 2022 Jan;14(1):77-89. doi: 10.2217/imt-2021-0251. Epub 2021 Dec 1. Immunotherapy. 2022. PMID: 34850647 Clinical Trial.
-
One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.J Dermatol. 2017 Apr;44(4):375-385. doi: 10.1111/1346-8138.13644. Epub 2016 Nov 14. J Dermatol. 2017. PMID: 27862227 Free PMC article. Clinical Trial.
-
Bilastine for the treatment of urticaria.Expert Opin Pharmacother. 2013 Aug;14(11):1537-44. doi: 10.1517/14656566.2013.800044. Epub 2013 May 16. Expert Opin Pharmacother. 2013. PMID: 23675825 Review.
-
Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria.Expert Opin Drug Saf. 2011 Sep;10(5):779-93. doi: 10.1517/14740338.2011.604029. Epub 2011 Aug 11. Expert Opin Drug Saf. 2011. PMID: 21831011 Review.
Cited by
-
Current treatment strategies for seasonal allergic rhinitis: where are we heading?Clin Mol Allergy. 2022 Aug 10;20(1):9. doi: 10.1186/s12948-022-00176-x. Clin Mol Allergy. 2022. PMID: 35948975 Free PMC article. Review.
-
Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis.Front Pharmacol. 2022 Jan 10;12:731201. doi: 10.3389/fphar.2021.731201. eCollection 2021. Front Pharmacol. 2022. PMID: 35082662 Free PMC article. Review.
-
Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions.Drugs Context. 2021 Aug 10;10:2021-5-1. doi: 10.7573/dic.2021-5-1. eCollection 2021. Drugs Context. 2021. PMID: 34457015 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
